PYC Therapeutics Issues New Shares Following Option Exercise and Lodges Cleansing Notice

PYC Therapeutics Limited ( (AU:PYC) ) has provided an update.

PYC Therapeutics has issued 250,000 fully paid ordinary shares following the exercise of an equivalent number of unlisted options priced at $0.90 each, with an expiry date in October 2027. The new shares are being quoted on the ASX, modestly increasing the company’s share capital and reflecting continued engagement with its long-term incentive arrangements.

The company also lodged a cleansing notice under section 708A(5)(e) of the Corporations Act, confirming that the shares were issued without a prospectus and that PYC remains compliant with its continuous disclosure and financial reporting obligations. By affirming that there is no excluded information requiring disclosure, PYC signals regulatory transparency to investors and supports the tradability of the newly issued shares on the market.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.84 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing a new generation of RNA therapies for patients with genetic diseases that currently lack treatment options. The company leverages a proprietary drug delivery platform to boost the potency of precision medicines within the expanding RNA therapeutics market, concentrating on monogenic diseases that offer a higher likelihood of clinical development success.

Average Trading Volume: 1,507,284

Technical Sentiment Signal: Buy

Current Market Cap: A$1.27B

Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.